Multiplex Respiratory Panel Integrates Automated Extraction to Streamline High-Volume Testing

Respiratory infections drive heavy testing volumes in clinical laboratories, where accurate, timely results across multiple pathogens are essential. Many labs are seeking to streamline workflows and increase throughput without sacrificing quality. A newly cleared workflow now integrates automated extraction with multiplex respiratory detection to support efficient, high-volume testing.

Applied BioCode’s (Los Angeles, CA, USA) BioCode Respiratory Pathogen Panel (RPP) has received U.S. Food and Drug Administration (FDA) clearance for in vitro diagnostic (IVD) use when paired with nucleic acid extraction on the Thermo Fisher Scientific (Waltham, MA, USA) KingFisher Flex platform. The update adds extraction claims that broaden the RPP workflow options available to clinical laboratories. It is designed to provide greater flexibility in how labs set up and run respiratory testing.

The workflow enables seamless integration of the KingFisher Flex extraction platform with the BioCode MDx-3000 automated detection system. According to the announcement, combining these systems expands the panel’s utility and increases throughput for respiratory testing. Laboratories can streamline operations by pairing the extraction platform and detection system with the RPP, described as an affordable, comprehensive solution for detecting 17 prevalent respiratory pathogens.

The clearance builds on prior FDA authorization of the company’s Gastrointestinal Pathogen Panel with the KingFisher Flex system, reflecting continued validation of flexible, high‑throughput extraction solutions across a multiplexed panel portfolio. The company indicates the new claim is expected to improve workflow efficiency and accelerate delivery of accurate, timely diagnostic results in high‑volume environments.

“Adding the Thermo Fisher KingFisher™ Flex extraction system demonstrates Applied BioCode’s commitment to delivering flexible, high-quality solutions for the molecular diagnostics market,” said Dr. Winston Ho, CEO and founder of the Applied BioCode. “This enhancement reinforces our commitment to enabling accurate and timely respiratory pathogen detection in high-volume testing environments.”

Related Links
Applied BioCode
Thermo Fisher Scientific